Get the Stockscreener App
5.97
8.29%
-0.54
After Hours:
5.82
-0.15
-2.51%
Turn Therapeutics Inc stock is traded at $5.97, with a volume of 469.66K.
It is down -8.29% in the last 24 hours and up +0.00% over the past month.
Turn Therapeutics Inc is a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble APIs in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis.
See More
Previous Close:
$6.51
Open:
$6.2
24h Volume:
469.66K
Relative Volume:
1.46
Market Cap:
$182.43M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+0.00%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.50
$6.3501
1-Week Range:
$5.50
$26.50
52-Week Range:
$5.50
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Compare TTRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
5.97 | 182.43M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics appoints Arthur Golden to board of directors By Investing.com - Investing.com Canada
Turn Therapeutics Appoints Arthur Golden to Board of Directors - MarketScreener
When Will Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Turn A Profit? - Yahoo
What Fibonacci levels say about Whitehawk Therapeutics Inc. reboundMarket Activity Summary & Consistent Profit Focused Trading Strategies - newser.com
Will Serina Therapeutics Inc. stock maintain growth storyJuly 2025 Review & Comprehensive Market Scan Reports - newser.com
What institutional flow reveals about Vivos Therapeutics Inc.Stock Surge & Long-Term Safe Investment Plans - newser.com
Abeona Therapeutics Inc. stock daily chart insightsJuly 2025 Momentum & AI Powered Buy and Sell Recommendations - newser.com
What risks investors should watch in Fulcrum Therapeutics Inc. stockWeekly Profit Analysis & Reliable Volume Spike Alerts - newser.com
Will Apogee Therapeutics Inc. stock split attract more investorsStock Surge & Safe Swing Trade Setup Alerts - newser.com
What machine learning models say about Elicio Therapeutics Inc.Profit Target & AI Forecasted Stock Moves - newser.com
Can trapped investors hope for a rebound in Unicycive Therapeutics Inc.Quarterly Earnings Summary & Intraday High Probability Setup Alerts - newser.com
Turn Therapeutics files prospectus relates to offer, sale of up to 7 mln shares - MarketScreener
Stock skyrockets after Turn goes public - BioWorld MedTech
Dow Dips Over 250 Points; Delta Air Lines Posts Upbeat Earnings - Benzinga
Turn Therapeutics (TTRX) Skyrockets After Nasdaq Debut – Biotech Breakthrough or Hype? - ts2.tech
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength? - Yahoo Finance
US Stocks Mixed; Nasdaq Falls Over 50 Points - Benzinga
Pre-Market Titans: TTRX, BJDX & UPC Set The Pace - RTTNews
Stock Market Today: S&P 500, Nasdaq Futures Slip As Fed Minutes Signal Tariff-Related Uncertainty—PepsiCo, Delta, Levi Strauss In Focus (UPDATED) - Benzinga
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today? - MSN
Turn Therapeutics Shares Skyrocket 134% After Hours Following Nasdaq Debut - Benzinga
After-Hours Surge: Turn Therapeutics Rockets 134% Post-Close On Nasdaq Debut; Biotech Stocks Rally - Nasdaq
Turn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics to Commence Trading Today on Nasdaq - Sahm
Turn Therapeutics (Direct Listing) Plans $0.00 IPO for Week of October 13th (TTRX) - Defense World
Sarepta Therapeutics Stock Skyrockets After FDA U-Turn – Gene Therapy Drama Explained! - ts2.tech
Turn Therapeutics Inc. Announces Board and Committee Appointments, Effective September 30, 2025 - MarketScreener
Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership - BioSpace
Crystalys Therapeutics Launches with $205M Series A Financing to Transform the Treatment of Gout - PR Newswire
Turn Therapeutics Announces Expected First Day of Trading on NASDAQ Global Market - Business Wire
Can Zevra Therapeutics (ZVRA) Turn Clinical Momentum Into Sustainable Competitive Advantage? - Yahoo Finance
This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
Strength Seen in Amicus Therapeutics (FOLD): Can Its 6.4% Jump Turn into More Strength? - Yahoo Finance
Turn Therapeutics to Host Open Investor Session in Connection with Expected Public Listing on Nasdaq - Business Wire
Strength Seen in Silicon Motion (SIMO): Can Its 6.4% Jump Turn into More Strength? - Yahoo Finance
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? - Yahoo Finance
After dropping IPO plans, Odyssey Therapeutics turns to VC for capital - The Business Journals
impact.com Announces Sustained Growth in Q2 2025 as Consumers Turn to Authentic Connections with Trusted Communities and Brands - Yahoo Finance
TTRX IPO NewsWound and dermatology-focused Turn Therapeutics files for a direct listing on the Nasdaq - renaissancecapital.com
Superbug Survivor and Turn Therapeutics CEO Launches Podcast to Spotlight Hidden Scientific Breakthroughs - Business Wire
Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P - The Economic Times
Turn Therapeutics Begins Clinical Trial of First Topical IL-36/IL-31 Inhibitor for Eczema - Business Wire
Junior Patriots™ Begins Initiative to Turn 1,000 Young Americans Into #1 Best Selling Authors in 2025 - Yahoo Finance
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts - baystreet.ca
This Sarepta Therapeutics Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength? - Yahoo Finance
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
China is catching up to the U.S. in pharmaceuticals, but it’s not too late to turn that around - Fast Company
Vertical Aerospace Ltd. (NYSE:EVTL) Is About To Turn The Corner - Yahoo Finance
Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade) - Seeking Alpha
Turn Therapeutics Inc Stock (TTRX) Financials Data
There is no financial data for Turn Therapeutics Inc (TTRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):